Cargando…

Assessment of health-related quality of life and health status in patients with treatment-resistant depression treated with esketamine nasal spray plus an oral antidepressant

BACKGROUND: Patients with treatment-resistant depression (TRD) report significant deficits in physical and mental health, as well as severely impaired health-related quality of life (HRQoL) and functioning. Esketamine effectively enhances the daily functioning in these patients while also improving...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jamieson, Carol, Popova, Vanina, Daly, Ella, Cooper, Kimberly, Drevets, Wayne C., Rozjabek, Heather M., Singh, Jaskaran
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10169482/ https://www.ncbi.nlm.nih.gov/pubmed/37158911 http://dx.doi.org/10.1186/s12955-023-02113-1

Ejemplares similares

Evaluation of Individual Items of the Patient Health Questionnaire (PHQ-9) and Montgomery-Asberg Depression Rating Scale (MADRS) in Adults with Treatment-Resistant Depression Treated with Esketamine Nasal Spray Combined with a New Oral Antidepressant
por: Floden, Lysbeth, et al.
Publicado: (2022)

Relationship Between Dissociation and Antidepressant Effects of Esketamine Nasal Spray in Patients With Treatment-Resistant Depression
por: Chen, Guang, et al.
Publicado: (2022)

Effect of Esketamine Nasal Spray on Olfactory Function and Nasal Tolerability in Patients with Treatment-Resistant Depression: Results from Four Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Studies
por: Doty, Richard L., et al.
Publicado: (2021)

Effects of Mu-Opiate Receptor Gene Polymorphism rs1799971 (A118G) on the Antidepressant and Dissociation Responses in Esketamine Nasal Spray Clinical Trials
por: Saad, Ziad, et al.
Publicado: (2020)

Assessing the meaningful change threshold of Quality of Life in Depression Scale using data from two phase 3 studies of esketamine nasal spray
por: Rozjabek, Heather, et al.
Publicado: (2022)

Long-term safety and maintenance of response with esketamine nasal spray in participants with treatment-resistant depression: interim results of the SUSTAIN-3 study
por: Zaki, Naim, et al.
Publicado: (2023)

Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1)
por: Fedgchin, Maggie, et al.
Publicado: (2019)

Benefit–Risk Assessment of Esketamine Nasal Spray vs. Placebo in Treatment‐Resistant Depression
por: Katz, Eva G., et al.
Publicado: (2020)

Efficacy and safety of esketamine nasal spray by sex in patients with treatment-resistant depression: findings from short-term randomized, controlled trials
por: Jones, Robyn R., et al.
Publicado: (2022)

Cardiac Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Results from the Clinical Development Program
por: Doherty, Teodora, et al.
Publicado: (2020)

Genome-wide association study and polygenic risk score analysis of esketamine treatment response
por: Li, Qingqin S., et al.
Publicado: (2020)

Adverse Events and Measurement of Dissociation After the First Dose of Esketamine in Patients With TRD
por: Williamson, David, et al.
Publicado: (2022)

U.S. Food and Drug Administration’s Patient-Focused Drug Development Initiative: Experience with Integration of Patient-Experience Data in a New Drug Application for Esketamine Nasal Spray Plus a Newly Initiated Oral Antidepressant for Treatment-Resistant Depression
por: Katz, Eva G., et al.
Publicado: (2021)

Montgomery‐Åsberg Depression Rating Scale factors in treatment‐resistant depression at onset of treatment: Derivation, replication, and change over time during treatment with esketamine
por: Borentain, Stephane, et al.
Publicado: (2022)

Long-term Safety and Efficacy of Esketamine Nasal Spray Plus an Oral Antidepressant in Patients with Treatment-resistant Depression– an Asian Sub-group Analysis from the SUSTAIN-2 Study
por: Jeon, Hong Jin, et al.
Publicado: (2022)

Is (S)-norketamine an alternative antidepressant for esketamine?
por: Hashimoto, Kenji, et al.
Publicado: (2018)

Managing dissociative symptoms following the use of esketamine nasal spray: a case report
por: Pereira, Sophia, et al.
Publicado: (2020)

Comment to Drs Gastaldon, Papola, Ostuzzi and Barbui
por: Mathews, Maju, et al.
Publicado: (2020)

Improvement of functional neurological disorder after administration of esketamine nasal spray: a case report
por: Vendrell-Serres, Júlia, et al.
Publicado: (2021)

Effects of esketamine on patient-reported outcomes in major depressive disorder with active suicidal ideation and intent: a pooled analysis of two randomized phase 3 trials (ASPIRE I and ASPIRE II)
por: Jamieson, Carol, et al.
Publicado: (2023)

Real-world approach to managing dysgeusia following the use of esketamine nasal spray: a case report
por: Bossaller, Nicholas A., et al.
Publicado: (2020)

Managing Esketamine Treatment Frequency Toward Successful Outcomes: Analysis of Phase 3 Data
por: Nijs, Michel, et al.
Publicado: (2020)

Esketamine Nasal Spray for Rapid Reduction of Depressive Symptoms in Patients With Major Depressive Disorder Who Have Active Suicide Ideation With Intent: Results of a Phase 3, Double-Blind, Randomized Study (ASPIRE II)
por: Ionescu, Dawn F, et al.
Publicado: (2020)

Esketamine Nasal Spray for the Rapid Reduction of Depressive Symptoms in Major Depressive Disorder With Acute Suicidal Ideation or Behavior
por: Canuso, Carla M., et al.
Publicado: (2021)

ESKALE study, a French real-world study of esketamine nasal spray for patients with treatment-resistant depression
por: Ludovic, S., et al.
Publicado: (2022)

Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Plus a Newly Initiated Oral Antidepressant in Adult Patients with Treatment-Resistant Depression: A Randomized, Double-Blind, Multicenter, Active-Controlled Study Conducted in China and USA
por: Chen, Xu, et al.
Publicado: (2023)

Effect of intranasal esketamine on cognitive functioning in healthy participants: a randomized, double-blind, placebo-controlled study
por: Morrison, Randall L., et al.
Publicado: (2018)

The effect of esketamine in patients with treatment‐resistant depression with and without comorbid anxiety symptoms or disorder
por: Daly, Ella J., et al.
Publicado: (2021)

Treatment Response of Add-On Esketamine Nasal Spray in Resistant Major Depression in Relation to Add-On Second-Generation Antipsychotic Treatment
por: Dold, Markus, et al.
Publicado: (2020)

ESKALE study, a French real-world study describing TRD patients with Esketamine nasal spray: final analysis
por: Samalin, L., et al.
Publicado: (2023)

Treating with esketamine nasal, will increase blood pressure?
por: Rosello-Molina, V., et al.
Publicado: (2021)

Effects of preoperative nasal spray esketamine on separation anxiety and emergence agitation in pediatric strabismus surgery: A randomized clinical trial
por: Liu, Wei, et al.
Publicado: (2022)

Early Clinical Experiences of Esketamine Nasal Spray in the UK in Adults with Treatment-Resistant Major Depressive Disorder: Advisory Panel Recommendations
por: Young, Allan H, et al.
Publicado: (2023)

Efficacy and Tolerability of Combination Treatments for Major Depression: Antidepressants plus Second-Generation Antipsychotics vs. Esketamine vs. Lithium
por: Vázquez, Gustavo H., et al.
Publicado: (2021)

Esketamine Nasal Spray Improves Rate and Time to Remission Versus Quetiapine Extended Release in Subgroups of Patients With Treatment Resistant Depression and Two or Three Plus Prior Treatment Failures: Results From ESCAPE-TRD, a Randomised Phase IIIb Trial
por: Young, A.H., et al.
Publicado: (2023)

Safety of esketamine nasal spray: Analysis of post-marketing reports submitted to the FDA adverse event reporting system in the first year on the market
por: Gastaldon, C., et al.
Publicado: (2021)

The antidepressant effect and safety of non-intranasal esketamine: A systematic review
por: Smith-Apeldoorn, Sanne Y, et al.
Publicado: (2022)

Metabolomic signatures of drug response phenotypes for ketamine and esketamine in subjects with refractory major depressive disorder: new mechanistic insights for rapid acting antidepressants
por: Rotroff, D M, et al.
Publicado: (2016)

Effect of Sleep Disturbance on Efficacy of Esketamine in Treatment-Resistant Depression: Findings from Randomized Controlled Trials
por: Borentain, Stephane, et al.
Publicado: (2021)

Use of Clinical Global Impressions-Severity (CGI-S) to Assess Response to Antidepressant Treatment in Patients with Treatment-Resistant Depression
por: Morrens, Joachim, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_fm6vduh9282cv157mv5p5iang6